

Freedom to Live Life Fully



A Global Leader in Large-
Volume Subcutaneous
Drug Delivery

Nasdaq: KRMD

Corporate Overview

August 2026

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements.

Forward-looking statements discuss the Company's current expectations and projections relating to its plans, objectives, future performance, business, outlook and financial projections. Forward-looking statements can be identified by words such as "vision", "expected", "estimated", "plan", "drivers", "path", "milestones", "opportunities" and "outlook", and include without limitation timing of international expansion, existence and timing of pharma trials, financial guidance for 2026, long-term financial goals, and timing of 510(k) and global submissions. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those associated with inflation, tariffs, war and other geopolitical conflicts, customer ordering patterns, availability and costs of raw materials and labor and our ability to recover such costs, future operating results, growth of new patient starts and the Ig market, our compliance with Food and Drug Administration and foreign authority regulations and the outcome of regulatory audits, introduction and adoption of competitive products, acceptance of and demand for new and existing products, ability to penetrate new markets, success in enforcing and obtaining patents, reimbursement related risks, government regulation of the home health care industry, success of our research and development effort, expanding the market of FREEDOMTM System, demand in the SClg market, availability of sufficient capital if or when needed, dependence on key personnel, and the impact of recent accounting pronouncements, as well as those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, which is on file with the SEC and available on our website at www.korumedical.com/investors. All information provided in this release and in the attachments is as of August 5, 2026, unless otherwise indicated. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

Revenues: All references to revenue(s) in this presentation refer to net revenues.

We enable, simplify, and enhance the delivery of large-volume subcutaneous (LVSC) drugs in the home and in the clinic

More Time For What Matters Most



Capitalizing on the ongoing shift from intravenous (IV) hospital settings to **subcutaneous (SC) therapy in the home and in infusion clinics**

Our subcutaneous Freedom Infusion System is, today, primarily used by **~60,000 chronic, recurring** subcutaneous immunoglobulin (SCIg) drug therapy patients

Expanding our market beyond SCIg via 8 current collaborations with pharmaceutical companies to bring **new drug therapies** onto our label

Leveraging a low cost go-to-market model by serving pharmaceutical companies, specialty pharmacies, home care networks, and distributors

KORU at a Glance



FREEDOM INTEGRATED INFUSION SYSTEM

~60k Global Patients



DRUG CLEARANCES / REGISTRATIONS

9 Drugs / 30+ Countries

First Subcutaneous Drug Clearance 2010



FY 2026 GUIDANCE

\$47.5-\$48.5M²; 15-18% y/y growth

62-64% Gross Margin

Positive Adj. EBITDA & Year End Cash Balance > \$7.5M




\$10M UNDRAWN DEBT FACILITY IN PLACE

\$8.3M² Cash Balance



HEADQUARTERS/MANUFACTURING

Mahwah, NJ




FY2025 REVENUES

\$41.1M¹

- Domestic Core
- International Core
- Pharma Services & Clinical Trials


Pharma Services and Clinical Trials

Revenue from pre-commercial pharmaceutical drug collaborations utilizing Freedom Infusion System



Domestic & International Core

Freedom Infusion System sales for on-label commercialized drugs



Pharmaceutical drug collaborations move to Core business following 510(k) clearance for use of the drug with the KORU Freedom Infusion System

KORU's Freedom Infusion System

Mechanical Pumps

~20% of revenues




Freedom60[®]
INFUSION SYSTEM




FreedomEDGE[®]
INFUSION SYSTEM

Customizable Consumables


~80% of revenues



Precision[™]
FLOW RATE TUBING



High-Flo[™]
SUBQ NEEDLE SET



**Simple, Easy-to-use,
Reusable mechanical
pump**




**97% Patient
adherence rate¹**




**Customizable
platform for use with
large-volume SC
drugs**

Global Ig Business Drives Annual Recurring Revenue Base



The Movement of Healthcare from Hospital to the Home Driving Large and Growing Subcutaneous Infusion Opportunity




KORU'S Strategic Growth Pillars



Our Opportunity

Shift from IV to SC is Driving a Sizeable and Growing Market of Large-Volume Subcutaneous (LVSC) Opportunities



Between 2020-2026, 13 drugs have launched, and the LVSC market has diversified, primarily in oncology

Oncology Market Opportunity

Currently 8 Subcutaneous Oncology Drugs Available on the Market Using Syringe Manual Push

DARZALEX Faspro®
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000 units

TECENTRIQ Hybreza™
atezolizumab/hyaluronidase-tqjs
SUBCUTANEOUS INJECTION 1875 mg/30,000 units

KEYTRUDA Qlex™
pembrolizumab + berahyaluronidase alfa-pmph
Subcutaneous Injection | 165 mg + 2,000 units/mL

Herceptin HYLECTA™
trastuzumab and hyaluronidase-oysk
INJECTION FOR SUBCUTANEOUS USE | 600 mg/10,000 units

PHESGO®
pertuzumab/trastuzumab/hyaluronidase-zzxf
SUBCUTANEOUS INJECTION | 1,200 mg/600 mg/30,000 units
600 mg/600 mg/30,000 units

RituxanHYCELA®
rituximab/hyaluronidase human
subcutaneous injection | 1,400 mg/23,400 Units
1,600 mg/26,800 Units

OPDIVO Qvantig™
nivolumab + hyaluronidase-nvhy
SUBCUTANEOUS INJECTION | 120 mg + 3,000 units / mL

RYBREVANT®²
(amivantamab-vmjw)
Injection for IV Use | 350 mg/7 mL (50 mg/mL)

~\$138M
2030¹ TAM



~\$60M
Oncology Infusion
Pump & Consumables
2025¹ TAM

Successful US Pilot Study Validated Value Proposition for KORU Freedom System in Infusion Clinics

- ✓ 100% of doses successfully administered
- ✓ ~70% of nurses reported ability to multitask, improving workflow efficiency
- ✓ High Nurse (4.8/5) and Patient (4.9/5) Satisfaction

Pipeline Opportunities in SCIg and New Drug Therapies

8 in Pipeline

9 on Label

Active Opportunities for New Drugs and Indications¹

Commercial

Phase III

Phases I & II

Estimated
KRMD Launch
0-1 Yr¹

Estimated
KRMD Launch
1-3 Yrs¹

Estimated
KRMD Launch
3-5 Yrs¹

Drug Asset

Annual Global
Infusions Estimate³

Deferoxamine ²	200k
Phesgo ⁵	600k

+

Empaveli [®] FSGS + DGF ⁶	25K + 25K
Endocrinology Drug	500k
Nephrology Drug	600k

+

Respiratory Drug	1M
ForCast Orthopedics	140k
Multi-Indication Drug	2.4M

Represents
~5.5M total
annual
infusions
worldwide

SCIg

5.4M³ Annual Infusions



Ig Collaborations for expanded indications and devices fuel share gains

Non-SCIg

<0.25M³ Annual Infusions




Non-Ig Drugs broadening platform⁴

1. Clearance dates are based on most recent estimation and are subject to change, 2. KRMD pursuing drug label independently 3. Annual infusion figures are estimates based on total patient population and dosing schedule. Not adjusted for clinical risk, 4. Empaveli[®] is the U.S. brand name, outside of the U.S. the therapy is marketed as Aspaveli[®] 5. Reflects continued international pursuit of Phesgo[®] opportunity; 510(k) application for U.S. use has been withdrawn. 6. Subject to changes based on pending Biogen/Apellis integration strategy

Financial Highlights

Revenue (\$M)



	1H 2026	1H 2025	Y/Y Δ
Revenue	\$23.8M	\$19.8M	+20% Growth
Gross Margin	63.3%	63.1%	+20bps
OpEx	\$15.3M	\$14.1M	+9% Increase
Net Loss	(\$0.6M)	(\$1.4M)	60% Improvement
Adj. EBITDA*	\$0.9M	\$0.02M	>1,000% Improvement
Cash Usage	(\$0.6M)	(\$1.5M)	62% Improvement

Strong
OpEx
Efficiency

Strategically Positioned for Accelerated Growth

Strong Fundamentals, Significant Opportunity¹

Large and growing market for SC drug delivery; ~95 >10mL drugs in development

Leading share in U.S. SCIg, gaining momentum internationally

Recurring revenue from ~60,000 patients on platform

New strategic catalysts in SID and connected health technology

~8 non-Ig pipeline drugs with RYSTIGGO®² and deferoxamine as near-term commercial opportunities

Recent Accomplishments¹

18% 2Q26 revenue growth over prior year period

2Q26 gross profit of \$7.8M; gross margin 65.1%

2Q26 cash usage of (\$0.5M); 17% y/y improvement

2Q26 Adj. EBITDA of \$0.9M; 900% y/y improvement

Long Term Financial Goals³


\$100M revenue

Accelerated double-digit revenue CAGR

>65% gross margins

+20% EBITDA margin

Sustained Pathway to +20% Growth



Key Growth Drivers

- Sustained share of SCIg market growth and share gains**
8-10% annual growth
- New product launches & innovation**
2nd generation consumables, Freedom360™, and flow controller
- Entry into new SCIg markets, expansion of established markets, vial to PFS conversions**
- New drugs on label**
Includes current pipeline

Execution Milestones on Path to Accelerated Revenue Growth

Adjusting 2026 Financial Guidance

- 15-18% revenue growth
- Positive Adjusted EBITDA, Cash of >\$7.5M
- Gross margin 62-64%

Enable More Drugs, Reach More Patients

- Add 4 new pipeline collaborations for FY26: 2 of 4 complete
- ✓ Deferoxamine 510(k) submitted in Q1 2026

Expand Internationally

- ✓ Freedom60 EU MDR clearance with PFS compatibility
- Launch of Freedom Infusion System with PFS in targeted markets
- Exploring expansion of oncology strategy in international markets

Protect and Grow our Core Domestic Business

- New non-Ig drugs on label
 - ✓ UCB RYSTIGGO® 510(k) clearance in Jan 2026
- 510(k) submission Freedom360™ (2026)
- 510(k) and global submissions Phase 2 flow controller (2H 2026 - 1H 2027)
- ✓ Outpace SCIg market growth of 8-10%



Appendix

Non-GAAP Financial Measures

This presentation includes the non-GAAP financial measures “adjusted EPS”, “adjusted diluted EPS”, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

Reconciliation of GAAP Net Income/(Loss) to Non-GAAP Adjusted EBITDA:	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
GAAP Net Income /(Loss)	\$ 252,449	\$ (206,867)	\$ (554,628)	\$ (1,373,104)
Depreciation and Amortization*	210,031	209,487	407,562	426,844
Interest (Income), Net	(59,870)	(78,951)	(140,866)	(152,130)
Stock-based Compensation Expense*	457,773	415,744	1,139,284	1,113,344
Adjusted EBITDA	\$ 860,383	\$ 339,414	\$ 851,351	\$ 14,953
Weighted Average Number Of Common Shares Outstanding				
Basic	46,083,893	46,193,709	46,223,623	46,088,353
Diluted	49,509,437	46,193,709	46,223,623	46,088,353
Reconciliation of Reported Diluted EPS to Non-GAAP Adjusted Diluted EPS:	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Reported Diluted Earnings Per Share	\$ 0.01	\$ (0.00)	\$ (0.01)	\$ (0.03)
Depreciation and Amortization*	0.00	0.00	0.01	0.01
Interest (Income), Net	(0.00)	(0.00)	(0.00)	(0.00)
Stock-based Compensation Expense*	0.01	0.01	0.02	0.02
Adjusted Diluted Earnings Per Share	\$ 0.02	\$ 0.01	\$ 0.02	\$ 0.00